Loading...
XLONAGL
Market cap40mUSD
Dec 27, Last price  
10.00GBP
1D
4.17%
1Q
21.21%
Jan 2017
-79.49%
Name

Angle PLC

Chart & Performance

D1W1MN
XLON:AGL chart
P/E
—
P/S
1,475.40
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.85%
Rev. gr., 5y
26.38%
Revenues
2m
+109.99%
4,093,0004,093,0003,377,0003,873,0005,064,0002,454,0002,420,0001,407,000969,023801,0000361,000498,000628,000678,000871,500762,0001,013,0001,041,0002,186,000
Net income
-20m
L-7.17%
-2,526,000-2,526,000-9,108,0001,210,000-3,595,000-44,000-354,000-2,585,000-865,738-1,064,000-3,594,000-4,893,000-6,567,000-7,556,000-8,942,000-11,334,000-11,606,000-15,012,000-21,686,000-20,132,000
CFO
-14m
L-9.92%
-3,919,000-3,919,000-6,227,000-2,264,000-790,000-461,000-810,000-1,081,000-1,392,101-2,235,000-3,422,000-4,762,000-7,383,000-6,812,000-7,314,000-8,327,999-7,848,000-14,010,000-16,050,000-14,458,000

Profile

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
URL
https://www.angleplc.com/
IPO date
Mar 17, 2004
Employees
173
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122019‑042018‑042017‑042016‑042015‑04
Income
Revenues
2,186
109.99%
1,041
2.76%
1,013
32.94%
Cost of revenue
12,476
5,473
4,085
Unusual Expense (Income)
NOPBT
(10,290)
(4,432)
(3,072)
NOPBT Margin
Operating Taxes
(1,500)
(2,753)
(2,351)
Tax Rate
NOPAT
(8,790)
(1,679)
(721)
Net income
(20,132)
-7.17%
(21,686)
44.46%
(15,012)
29.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
14
19,045
19,690
BB yield
-0.05%
-15.29%
-7.35%
Debt
Debt current
649
662
522
Long-term debt
8,459
9,340
4,154
Deferred revenue
Other long-term liabilities
396
216
257
Net debt
(7,110)
(21,894)
(27,163)
Cash flow
Cash from operating activities
(14,458)
(16,050)
(14,010)
CAPEX
(611)
(1,887)
(1,788)
Cash from investing activities
(203)
(1,751)
14,774
Cash from financing activities
(1,125)
18,096
18,991
FCF
(3,082)
(3,593)
6,160
Balance
Cash
16,218
31,896
31,839
Long term investments
Excess cash
16,109
31,844
31,788
Stockholders' equity
(92,979)
(75,753)
(58,974)
Invested Capital
120,868
120,375
100,889
ROIC
ROCE
EV
Common stock shares outstanding
260,888
246,580
225,073
Price
0.12
-76.73%
0.51
-57.56%
1.19
149.21%
Market cap
30,654
-75.38%
124,523
-53.51%
267,837
215.06%
EV
23,544
102,629
240,674
EBITDA
(8,463)
(1,594)
(1,585)
EV/EBITDA
Interest
325
368
157
Interest/NOPBT